Clinical Trials Browser

Terminated × selinexor × Lymphoid × Clear all

NCT02314247 2023-01-26

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Phase 2 Terminated

16 enrolled 16 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral